We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is CVS Stock a Buy as Earnings Improve but Key Risks Remain Elevated?
Read MoreHide Full Article
Key Takeaways
CVS raised 2026 adjusted EPS guidance to $7.90-$8.10 as earnings momentum improves.
CVS raised Aetna's 2026 outlook to $5.03-$5.37 billion, more than $1 billion above earlier guidance.
CVS faces elevated medical costs, reimbursement pressure and a Caremark 2027 earnings headwind.
CVS Health (CVS - Free Report) is entering the second half of 2026 with stronger earnings momentum, higher cash generation and an improved Aetna profit outlook. Those gains strengthen the recovery case after a difficult period for the insurer.
The trade-off is that medical-cost pressure and changing pharmacy benefit manager economics remain unresolved. CVS trades below major valuation benchmarks, but its multiple is already above its own five-year median.
CVS Earnings Recovery Is Gaining Traction
The Zacks Consensus Estimate for 2026 earnings has increased 7.9% over the prior four weeks, while projected 2026 EPS growth stands at 16.6%. Current cash flow growth of 65.3% adds another positive signal.
Second-quarter results support that trend. Adjusted EPS increased 42.5% year over year to $2.58, while adjusted operating income rose 35.4% to $5.16 billion. CVS also raised 2026 adjusted EPS guidance to $7.90-$8.10.
Image Source: Zacks Investment Research
CVS Valuation Looks Low Versus Key Benchmarks
CVS trades at 11.7X forward 12-month earnings, below the Zacks sub-industry's 16.2X and the S&P 500's 20.8X. The gap shows that investors still assign CVS a sizable discount despite improving earnings.
Image Source: Zacks Investment Research
The stock is less cheap against its own history. CVS' five-year median forward multiple is 10.3X, below the current level. Relative valuation is favorable, but the shares are not unusually inexpensive compared with their historical norm.
CVS Aetna Recovery Strengthens the Bull Case
Health Care Benefits is the clearest operating reason for greater confidence. Adjusted operating income increased by more than $2 billion year over year in the first half of 2026 as pricing discipline and medical-cost management improved profitability.
CVS raised the segment's 2026 adjusted operating income outlook to $5.03-$5.37 billion, more than $1 billion above prior guidance. The medical benefit ratio improved to 87.4% in the second quarter from 89.9% a year earlier, showing measurable progress in the margin-recovery plan.
CVS PBM and Medical Risks Limit the Upside
The recovery still faces pressure from elevated medical utilization and reimbursement changes. CVS continues to take a prudent view of second-half medical costs, while retail pharmacy and pharmacy services face reimbursement and client-pricing pressure.
Caremark adds uncertainty. Weaker 340B conditions are expected to create a 2027 earnings headwind, while management anticipates lower pharmacy benefit manager membership next year. Specialty pharmacy and generic opportunities may offset part of that pressure, but uneven earnings remain possible.
The Cigna Group (CI - Free Report) is relevant because its Evernorth Health Services business includes pharmacy benefit and related health-service operations. Cigna therefore offers another diversified model exposed to benefit-management economics.
UnitedHealth Group (UNH - Free Report) combines a large insurance franchise with health-services operations through Optum. It provides another useful reference point for investors assessing medical-cost and health-services trends across managed care.
CVS Signals Point to a Balanced Setup
The bottom line is that CVS has better earnings momentum and a favorable relative valuation, but execution risk remains. Aetna is improving, while medical utilization, reimbursement pressure and Caremark's 2027 reset argue for more evidence that the gains can persist.
CVS currently carries a Zacks Rank #3 (Hold), which fits that mixed setup rather than signaling an aggressive entry point. The stock also has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those scores indicate favorable characteristics across several styles, but they are designed to complement the Zacks Rank.
View the Zacks #1 Rank List
Image: Bigstock
Is CVS Stock a Buy as Earnings Improve but Key Risks Remain Elevated?
Key Takeaways
CVS Health (CVS - Free Report) is entering the second half of 2026 with stronger earnings momentum, higher cash generation and an improved Aetna profit outlook. Those gains strengthen the recovery case after a difficult period for the insurer.
The trade-off is that medical-cost pressure and changing pharmacy benefit manager economics remain unresolved. CVS trades below major valuation benchmarks, but its multiple is already above its own five-year median.
CVS Earnings Recovery Is Gaining Traction
The Zacks Consensus Estimate for 2026 earnings has increased 7.9% over the prior four weeks, while projected 2026 EPS growth stands at 16.6%. Current cash flow growth of 65.3% adds another positive signal.
Second-quarter results support that trend. Adjusted EPS increased 42.5% year over year to $2.58, while adjusted operating income rose 35.4% to $5.16 billion. CVS also raised 2026 adjusted EPS guidance to $7.90-$8.10.
Image Source: Zacks Investment Research
CVS Valuation Looks Low Versus Key Benchmarks
CVS trades at 11.7X forward 12-month earnings, below the Zacks sub-industry's 16.2X and the S&P 500's 20.8X. The gap shows that investors still assign CVS a sizable discount despite improving earnings.
Image Source: Zacks Investment Research
The stock is less cheap against its own history. CVS' five-year median forward multiple is 10.3X, below the current level. Relative valuation is favorable, but the shares are not unusually inexpensive compared with their historical norm.
CVS Aetna Recovery Strengthens the Bull Case
Health Care Benefits is the clearest operating reason for greater confidence. Adjusted operating income increased by more than $2 billion year over year in the first half of 2026 as pricing discipline and medical-cost management improved profitability.
CVS raised the segment's 2026 adjusted operating income outlook to $5.03-$5.37 billion, more than $1 billion above prior guidance. The medical benefit ratio improved to 87.4% in the second quarter from 89.9% a year earlier, showing measurable progress in the margin-recovery plan.
CVS PBM and Medical Risks Limit the Upside
The recovery still faces pressure from elevated medical utilization and reimbursement changes. CVS continues to take a prudent view of second-half medical costs, while retail pharmacy and pharmacy services face reimbursement and client-pricing pressure.
Caremark adds uncertainty. Weaker 340B conditions are expected to create a 2027 earnings headwind, while management anticipates lower pharmacy benefit manager membership next year. Specialty pharmacy and generic opportunities may offset part of that pressure, but uneven earnings remain possible.
The Cigna Group (CI - Free Report) is relevant because its Evernorth Health Services business includes pharmacy benefit and related health-service operations. Cigna therefore offers another diversified model exposed to benefit-management economics.
UnitedHealth Group (UNH - Free Report) combines a large insurance franchise with health-services operations through Optum. It provides another useful reference point for investors assessing medical-cost and health-services trends across managed care.
CVS Signals Point to a Balanced Setup
The bottom line is that CVS has better earnings momentum and a favorable relative valuation, but execution risk remains. Aetna is improving, while medical utilization, reimbursement pressure and Caremark's 2027 reset argue for more evidence that the gains can persist.
CVS currently carries a Zacks Rank #3 (Hold), which fits that mixed setup rather than signaling an aggressive entry point. The stock also has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those scores indicate favorable characteristics across several styles, but they are designed to complement the Zacks Rank.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.